

Respiratory Viruses in Luxembourg (ReViLux)

Weekly report - 18 April 2023

Executive summary

The sentinel network detected a low epidemic activity over the last week (2023/15), based on 3.4% of consultations being associated with influenza- like illness. However, overall reported consultations were low due to holiday season. Among the specimen collected by the sentinel network over the last two weeks, the percentage of positive tests for Influenza B was 20.7%, followed by Human rhinovirus (15.4%) and SARS- CoV-2 (15.4%). Overall, during this season, Influenza A (H3) with 88.5 % is the most frequent detected strain in submitted specimens. However, starting from week 05/2023 higher circulation of type B virus was observed.

Concerning SARS-CoV-2 genomic surveillance, the recombinant sub-variant XBB.1.5 remains the most frequent detected variant with 35.2 % (95%CI: 27.4-42.9%), followed closely by XBB.1.9 with 30.3% (95%CI: 22.9-37.8%). The proportion of other recombinant XBB (excluding XBB.1.5 and XBB.1.9) has sharply increased from 1.3% (95%CI: 0-2.5%) in week (2023/13) to 17.2% (95%CI: 11.1-23.4%) in week (2023/14), because mutations are also emerging within these sub-variants.

IN THE SPOTLIGHT

Influenza characterization

Between weeks 2022/40 and 2023/06, a total of 446 influenza positive samples have been sent to LNS. Combined sentinel and non-sentinel data showed that most viruses detected were type A with 85% and type B with 15%. During this time-period, Influenza A (H3N2) dominated with 91.9% compared to 8.1% of influenza A (H1pdm) viruses.

Of these 446 samples reported, 258 samples (58%) were further genetic characterized. 198 Influenza A(H3N2) samples (100%) were attributed to subclade 3C.2a1b.2a.2, which is the same clade as the recommended vaccine virus strain for use in 2022/23. Furthermore, all Influenza A (H1, N=14) were represented by clade 6B.1A.5a.2 (like the virus component for 2022/23 vaccine).

All Influenza B samples (N=47) further characterized, belonged to Victoria lineage subgroup V1A.3a.2, represented by the recommended vaccine strain B/Austria/1359417/2021 for this season. No B/Yamagata-lineage viruses were detected.

Introduction

The Laboratoire national de santé, as **National Reference Laboratory for Acute Respiratory Infections** in Luxembourg, performs close surveillance on respiratory viruses, with a special focus on SARS-CoV-2. The main monitoring activities are:

- **The Sentinel Surveillance.** It provides a broad picture of respiratory diseases affecting the Luxembourgish population, based on clinical and laboratory data.
- **The SARS-CoV-2 Genomic Surveillance.** It enables detailed observation of SARS-CoV-2 variants and mutations through time and space, as well as studying specific groups of interest.

The objective of the ReViLux report is to inform public health actions in Luxembourg.

Sentinel Surveillance Network

The Sentinel Surveillance aims at monitoring the circulating respiratory viruses, from traditional ones like Influenza to more recent ones like SARS-CoV-2, and hence underpin public health actions. The Sentinel Network is a group of general practitioners and paediatricians spread over the country. They report the weekly number of patients showing symptoms suggestive of acute respiratory infection (ARI) and influenza-like illness (ILI), and those patients are then sampled and tested for a panel of respiratory viruses. The circulation of respiratory viruses in the north hemisphere is generally monitored by seasons that go from week 40 to week 20. The period between weeks 20 and 40 is usually called interseason.

Clinical results

Last week, 3.4% of consultations were reported as ILI, which represents a low epidemic activity for Luxembourg, according to ECDC and the Moving Epidemic Method. However, overall survey return rates were low due to holiday season and need to be interpreted with caution. The history of ILI consultations is displayed in Figure 1, and a detailed summary of the number of ARI and ILI cases during the last four weeks is included in Table 1.

Laboratory results

Over the last two weeks, the most frequently detected viruses (according to positivity rates) were Influenzavirus B (20.7%), Human rhinovirus (15.4%) and SARS-CoV-2 (15.4%). An overview of the viral circulation during the current season is displayed in Figure 2 and Table 2.




Figure 1. Percentage of patients with influenza-like illness over the last three seasons
Background colours according to intensity of circulation: low, medium, high, very high.

Table 1. Syndromic surveillance over the last 4 weeks

Week	ARI		ILI		Total consultations
	N	%	N	%	
2023/12	72	18.23	29	7.34	395
2023/13	63	15.14	28	6.73	416
2023/14	40	21.86	15	8.20	183
2023/15	11	7.53	5	3.42	146

ARI: Acute Respiratory Infections; ILI: Influenza-Like Illness.




Figure 2. Distribution of respiratory viruses detected within the Sentinel Network, by two-week periods. Results from last weeks are not yet consolidated.

FLU-A: influenza virus A; FLU-B: influenza virus B; PIV: parainfluenza virus; RSV: respiratory syncytial virus; ADV: adenovirus; MPV: metapneumovirus; HRV: human rhinovirus; SC2: SARS-CoV-2.

Table 2. Distribution of respiratory viruses detected within the Sentinel Network over the last 2 weeks compared to the whole current season.

Virus	Last 2 weeks		Season 2022/2023	
	N*	Positivity rate (%)	N*	Positivity rate (%)
Influenzavirus B	19	20.7	319	12.7
Human rhinovirus	8	15.4	435	19.2
SARS-CoV-2	14	15.4	304	17.4
Parainfluenzavirus	4	7.7	41	1.8
Adenovirus	2	3.8	209	9.2
Metapneumovirus	2	3.8	139	6.1
Influenzavirus A	2	2.2	408	16.3
Respiratory syncytial virus	0	0.0	208	9.2
Total	51		2063	

*Co-infection cases counted once for each virus detected.

Genotyping analyses

In order to assess the circulation of viral strains, genotyping analyses were also performed for Influenzavirus A and Respiratory syncytial virus (RSV) (Figure 3). During the current season, the most frequently detected strain for Influenzavirus A was H3 (88.5%), and for RSV it was type B (74.7%).




Figure 3. Detection of influenza virus-A (Flu-A) and Respiratory syncytial virus (RSV) strains in sentinel samples during the current season.

SARS-CoV-2 Genomic Surveillance

SARS-CoV-2 has posed a serious threat to the world population since 2020, and it is still a challenge for health systems. For this reason, the National Reference Laboratory for Acute Respiratory Infections at LNS continues to monitor the genomic characteristics of the SARS-CoV-2 virus detected in Luxembourg.

LNS receives positive specimens (nasopharyngeal or oropharyngeal swabs analysed by RT-PCR) from the national network of laboratories. All hospital specimens are sequenced, as well as a representative selection of community specimens. Illumina and Nanopore devices are used respectively. When needed, an additional screening by targeted PCR is also performed to enable earlier evaluation of the spread of newly emerging variants.

Bioinformatic analyses are based on a standardised pipeline, and lineage assignment is performed through the PANGOLin software (4.2, pango-data 1.19, mode UShER). In order to allow easier visualisation, WHO and Nextstrain categorisations are also used.

Sequencing activity

In week 2023/14, a total of 313 new cases were registered in Luxembourg; hence, the minimum sample size required to detect emerging variants at a 5% incidence is estimated to be 152 specimens (48.6%). The microbial genomics unit at LNS sequenced 168 specimens from the week of study, including 150 national ones (sequencing coverage: 47.9%; see Figure 4). This sample size is closed to the recommended sample size.




Figure 4. Number of specimens sequenced and national coverage based on weekly number of positive cases in Luxembourg. The coverage from the last two weeks is not consolidated yet.

Variant circulation

The 'XBB.1.5 like' variants remain the main variants of interest within the representative sample, the most frequent sub-variants being XBB.1.5 and XBB.1.9. Of note, XBB.1.5 decreased from 55.1% in week (2023/13) to 35.2% in week (2023/14). However, mutations are also emerging within these sub-variants, developed from Omicron. The proportion of other recombinant XBB variants (excluding XBB.1.5 and XBB.1.9) increased sharply from week 2023/13 to week 2023/14, from 1.3 to 17.2 % respectively.

An overview of the variants and lineages circulating over the last weeks is displayed in Figure 5, and further details are shown in Table 3. The history of the circulation of each variant since January 2021 is displayed in Figure 6.




Figure 5. Distribution of lineages within the representative sample during the last 10 weeks.

Table 3. Distribution of SARS-CoV-2 lineages detected within the representative sample during the last two weeks. Previously reported cases might be updated by retrospective analysis.

Lineage*	Week 13		Week 14	
	%	CI %	%	CI %
Recomb XBB.1.5	54.6	48.1 - 61.1	35.2	27.4 - 42.9
Recomb XBB.1.9	35.2	29.0 - 41.5	30.3	22.9 - 37.8
Recomb XBB	1.3	0.0 - 2.8	17.2	11.1 - 23.4
Omicron BA.2.75	4.0	1.4 - 6.5	6.2	2.3 - 10.1
Omicron BQ.1	3.5	1.1 - 5.9	4.1	0.9 - 7.4
Omicron BA.5	0.9	0.0 - 2.1	4.1	0.9 - 7.4
Others	0.4	0.0 - 1.3	2.8	0.1 - 5.4

*Sub-lineages are not included in the count of their parental lineages (e.g. BQ.1 not included in BA.5).
CI: confidence interval at 95%.




Figure 6. Proportion of each variant circulating in Luxembourg since January 2021.

Clinical and epidemiological factors

In this section, the lineage distribution of all specimens sequenced over the last month is assessed by demographics (sex and age group, Figure 7) and sampling setting (community vs. hospital, Table 4).




Figure 7. Age group and sex distribution of specimens sequenced over the last 4 weeks, by lineage.

Table 4. Comparison of lineage distribution by sampling setting.

Lineage	Community			Hospital		
	Women	Men	Total	Women	Men	Total
Recomb XBB.1.5	65.7%	65.3%	65.5%	57.5%	56.4%	57.0%
Recomb XBB.1.9	34.3%	34.7%	34.5%	42.5%	43.6%	43.0%
Total	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Mutation surveillance

In addition to the surveillance of SARS-CoV-2 variants, the LNS monitors the occurrence of SARS-CoV-2 mutations, as their early detection might be key to foresee changes in the epidemic evolution. The LNS is currently monitoring mutations to the spike protein, following ECDC guidance, and comparing their prevalence to that observed in Europe (according to GISAID).

Among the specimens collected over the last four weeks, we detected a higher circulation of the following mutations in Luxembourg (compared to Europe):

Table 5. Mutations detected at a higher proportion in Luxembourg

Lineage	Mutation	Gene	% in LU	% in EU	Ratio
BA.5	G339H	S	95.56	9.6	9.96
BA.5	G257S	S	72.55	12.2	5.96
BA.5	K444T	S	79.27	21.8	3.64
BA.5	N460K	S	96.63	37.1	2.60
XBB	Q613H	S	13.84	5.6	2.48
BQ.1	F157L	S	26.83	12.2	2.20
BA.5	R346T	S	97.73	53.3	1.83
BA.2.75	N185D	S	40.00	34.5	1.16
XBB.1.9	D405N	S	100.00	<5.00	-
XBB.1.9	K417N	S	100.00	<5.00	-
XBB.1.9	F486P	S	50.00	<5.00	-
XBB.1.5	F486P	S	88.89	<5.00	-
XBB.1.9	N501Y	S	100.00	<5.00	-
XBB.1.9	P681H	S	100.00	<5.00	-
BA.5	Q613H	S	12.85	<5.00	-

LU: Luxembourg; EU: Europe

References

Centers for Disease Control and Prevention. SARS-CoV-2 Variant Classifications and Definitions. Retrieved 18 April 2023, from <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html>

European Centre for Disease Prevention and Control. Guidance for representative and targeted genomic SARS-CoV-2 monitoring – 3 May 2021. ECDC : Stockholm ; 2021

European Centre for Disease Prevention and Control. SARS-CoV-2 variants of concern. Retrieved 18 April 2023, from <https://www.ecdc.europa.eu/en/covid-19/variants-concern>

European Centre for Disease Prevention and Control. Communicable Disease Threats Report Week <https://www.ecdc.europa.eu/en/publications-data/communicable-disease-threats-report-9-15-april-2023-week-15>

Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health. Geneva: World Health Organization; 2021.

GISAID. EpiCoV – Pandemic coronavirus causing COVID-19. Retrieved 5 mai 2022, from <https://www.gisaid.org>

GitHub - cov-lineages/pangolin: Software package for assigning SARS-CoV-2 genome sequences to global lineages. (2021). Retrieved 18 April 2023, from <https://github.com/cov-lineages/pangolin>

Hadfield J., Megill C., Bell S., Huddleston J., Potter B., Callender C. et al. (2018). Nextstrain: real-time tracking of pathogen evolution. *Bioinformatics*, 34(23), 4121-4123. doi: 10.1093/bioinformatics/bty407

Rambaut A., Holmes E., O’Toole Á., Hill V., McCrone J., Ruis C. et al. (2020). A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nature Microbiology*, 5(11), 1403-1407. doi: 10.1038/s41564-020-0770-5

The Luxembourgish data platform. COVID-19: Rapports hebdomadaires. Retrieved 18 April 2023, from <https://data.public.lu/en/datasets/covid-19-rapports-hebdomadaires/>